Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice

被引：0
|
作者：
Maerten, Angela [1 ]
Brueckl, Wolfgang [2 ]
Laack, Eckhart [3 ]
Hoffmann, Christopher [1 ]
Zhou, Caicun [4 ]
Wu, Yi-Long [5 ,6 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] Paracelsus Med Univ, Gen Hosp Nuernberg, Nurnberg, Germany
[3] Hamatoonkol Hamburg, Hamburg, Germany
[4] Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
LUNG-CANCER;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
337
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [1] Afatinib in EGFR Mutation-Positive (EGFRm plus ) NSCLC Harbouring Uncommon Mutations: Experience in 'Real-World' Clinical Practice
    Brueckl, W.
    Laack, E.
    Hoffmann, C.
    Zhou, C.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S671
  • [2] Afatinib in Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data
    Arrieta, O.
    De Marchi, P.
    Yamamoto, N.
    Yu, C.
    Ou, S. I.
    Zhou, C.
    Paskevicius, M.
    Maerten, A.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S165 - S165
  • [3] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommonmutations: Overview of clinical data
    Maerten, A.
    Yamamoto, N.
    Yu, C-J.
    Ou, S-H. I.
    Zhou, C.
    Wu, Y-L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S95 - S95
  • [4] UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
    Miura, S.
    Maerten, A.
    Popat, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1405 - S1406
  • [5] Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC harboring uncommon mutations
    Yang, J. C-H.
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S860 - S861
  • [6] Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Major Uncommon Mutations
    Yang, J. Chih-Hsin
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S31 - S31
  • [7] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Yang, T-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S776 - S777
  • [9] UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations.
    Miura, Satoru
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Yang, Tsung-Ying
    Park, Cheol-Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Maerten, Angela
    Popat, Sanjay
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
    Halmos, Balazs
    Tan, Eng-Huat
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian J.
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward S.
    Melosky, Barbara L.
    Maerten, Angela
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345